Citations

Clear

6055 citation(s) found for "Wu, Peter".

Considerations for using amyloid-targeting therapies for the treatment of early symptomatic Alzheimer’s disease
Budson, Andrew E. , Ljubenkov, Peter A., Ritter, Aaron , Leahy, Cara, Brosch, Jared, Burke, Anna, Matthews, Brandy R., Ljubenkov, Peter A. , Ramanan, Vijay K. , Brosch, Jared R.

Mayo Clinic

Frontiers in Neurology | August 11, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fneur.2026.1863897 | PMID 42643714 Get It

Amyloid-targeting therapies (ATTs), including donanemab and lecanemab, are FDA-approved disease-modifying therapies for Alzheimer’s disease in the mild cognitive impairment or mild dementia stages. Early initiation is important for optimal outcomes. This article summarizes practical strategies for implementing ATTs in clinical practice, focusing on leadership alignment and infrastructure development, as well as patient identification, diagnosis, and monitoring protocols. Key recommendations include establishing appropriate patient tracking systems, infusion and imaging protocols, and interprofessional collaboration. Approaches for systematic patient routing (e.g., hub-and-spoke models, fast-track mechanisms) and biomarker-integrated assessments are critical to facilitating timely diagnosis and treatment. Education for patients, care partners, and clinicians is crucial for managing the risks associated with amyloid-related imaging abnormalities. Successful ATT implementation requires coordinated systems, timely diagnosis, and robust safety monitoring. These measures can enable frameworks for ATT administration to optimize outcomes for patients, care partners, and health systems.
Cellular senescence is associated with age-related loss of liver zonation and hepatocyte function
Laux, L , Aristel, Alisha, Ali, Syed, Evensen, K. Garrett , Havas, Aaron , Miao, Zhen , Zhang, Jane, Peters, Samuel, Hu, Jiayi , Angelini, Luise, Klaers, Maggie, Brocksome, Jennie, Lewis, Adam , Paidimukkala, N., Brown, Mary E., Carver, Chase M., Albrecht, Jeffrey H. , Wehner, April , Adams, Peter, Aliferis, Constantin, Adeyi, Oyedele, Dong, Xiao, Wang, Jinhua, Zhang, Nancy, Adeyi, Oyedele , Adeyi, Oyedele , Lande, Kathryn , Li, Meiyi , Havas, Aaron , Zhang, Jane, Peters, Sam , Angelini, Luise, Brown, Mary E., Carver, Chase Matthew , Schafer, Marissa , Khosla, Sundeep , Wang, Jinhua , Robbins, Paul D. , Niedernhofer, Laura J. , Miao, Zhen , Khosla, Sundeep , Niedernhofer, Laura J

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.08.743614 | PMID 42845483 Get It

Abstract The liver is organized into tightly regulated zones with distinct metabolic functions but zonation erodes with age. Cellular senescence contributes to aging and liver diseases, however, its impact on aging biology is ill-defined. As part of The Cellular Senescence Network Consortium, we used multiple spatial transcriptomics approaches (GeoMx, Visium, CosMx) with snRNA-seq to profile senescence signatures, zonation markers, and metabolic pathways in livers from wild-type (WT) mice of multiple ages. We observed a loss of canonical zone signatures in aged mouse livers characterized by “expansion” of midlobular (zone 2) marker gene expression, accompanied by diminished expression of zone 3 marker genes by middle-age (18 months), indicative of loss of cell identity. Multiple analytic approaches identified distinct age-, zone- and sex-specific senescence signatures, which were significantly associated with zonation markers changes. This was recapitulated in Ercc1 mutant models of accelerated senescence, supporting a causal role of senescent cells in liver aging. A “no-zone” hepatocyte-like cluster expanded with age and with the strongest Senescence-Associated Secretory Phenotype (SASP) profile. Gene expression profiles from senescent hepatocytes implicate decreased WNT signaling and increased BMP as contributing to age-related loss of zonation. Together, these data elucidate the role of senescent cells in driving aging biology in non-diseased liver through disruption of cell:cell signaling and the loss of metabolic and cell identity gene expression necessary for hepatocyte function.
The Missing Foundation: Why Digital Architecture Must Be Health Care’s Next Priority
Bertagnolli, Monica, Chopra, Aneesh, Embí, Peter, Halamka, John, Illing, Rowwland, Lee, Peter, Mandl, Kenneth, Payne, Philip, Bertagnolli, Monica M. , Chopra, Aneesh , Embí, Peter J. , Halamka, John , Illing, Rowwland, Lee, Peter , Mandl, Kenneth D. , Payne, Philip

Mayo Clinic

NAM Perspectives | August 10, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.31478/202608a Get It

Physiology-guided cardioneuroablation for vagally mediated syncope and functional bradyarrhythmias
Kowlgi, Gurukripa N. , Pachón-M, José Carlos , Prasitlumkum, Narut , Gulati, Arvind, Yoo, Jeanwoo , Karlen, Kallie, Tan, Nicholas Y. , Sugrue, Alan , Killu, Ammar M. , Deshmukh, Abhishek , Munoz, Freddy Del‐Carpio , Siontis, Konstantinos C. , Madhavan, Malini , Friedman, Paul A. , Pachon-Mateos, Enrique, Pachon, Carlos, Acosta, Juan , Cha, Yong‐Mei , Shen, Win‐Kuang , Kowlgi, Narayan G , Prasitlumkum, Narut , Pachon, Jose C , Gulati, Arvind, Kapa, Suraj , DeSimone, Christopher V. , Noseworthy, Peter A. , Mateos, Enrique I. Pachon-, Pachon, Carlos Thiene C., Asirvatham, Samuel J.

Mayo Clinic

No container title available | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.03.26359633 Get It

Abstract Background Vagally mediated syncope and functional bradyarrhythmias can cause recurrent symptoms, injury and a need for permanent pacing, yet standard therapies do not address the underlying autonomic reflex. Cardioneuroablation (CNA) targets this mechanism, but adoption has been limited by uncertainty about patient selection, procedural endpoints and durable outcomes. Methods We studied 95 consecutive patients with vagally mediated syncope (n=78) or functional bradyarrhythmia (n=17) who underwent CNA at a single center by a single lead operator under a uniform, prospectively maintained protocol. Extracardiac vagal stimulation (ECVS) was performed before and after ablation to confirm vagally mediated sinus or atrioventricular (AV) nodal responses and to verify their attenuation. Outcomes through 1 year included clinical recurrence, quality of life, pacing burden and pacemaker extraction. Results Before ablation, ECVS provoked sinus pauses in 95.8% of patients and AV block in 91.6%; after ablation, sinus pauses were abolished in every patient and residual AV block was present in 4.2%. One-year freedom from recurrent syncope and from bradyarrhythmia-related events was 93.8% and 94.1%. Syncope burden fell from a median of 2.7 episodes per year to none, and disease-specific quality of life improved substantially (P<0.001). Among patients with pre-existing devices, atrial pacing burden fell from a median of 22% to 0%. There were no strokes, deaths or myocardial infarctions. Conclusions In this single-center cohort, physiology-guided CNA was associated with durable symptom control, improved quality of life and reduced pacing across vagally mediated bradyarrhythmia syndromes. Multicenter controlled studies are needed to confirm these findings.
Natural history of Impella 5.5 in patients with cardiogenic shock and small left ventricular cavities
Desai, Aarti, Wlodkowski, Peter, Klingbiel, Rebecca, Alak, Çetin , Ruiz, Jose, Shapiro, Anna, Martin, Archer, Nativi, Jose, Goswami, R., Klingbeil, Rebecca , Mautong, Hans , Klingbeil, R. , Ruiz, Jose , Nativí, Jose

Mayo Clinic

Frontiers in Cardiovascular Medicine | August 5, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1893068 | PMID 42630958 Get It

The Impella 5.5 is an axillary mechanical circulatory support device used in patients with cardiogenic shock, but those with small left ventricular (LV) cavities may be at risk for suction events, hemolysis, malpositioning, hypoperfusion, and LV injury. Informally accepted guidelines, extrapolated from durable LVAD studies, suggest a minimum left ventricular internal dimension in diastole (LVIDd) of 58 mm, with some clinical practices using a more stringent ≤52 mm cutoff. We retrospectively analyzed 154 consecutive patients supported with Impella 5.5 between January 2020 and December 2024. Overall, 38 patients had an LVIDd ≤58 mm, and 116 had an LVIDd &gt;58 mm; a key subgroup of 21 patients presented with a very small LVIDd of ≤52 mm]. Baseline demographics, comorbidities, body mass index, and renal function were similar [across groups], although those with larger LVIDd had lower ejection fractions (16% vs. 24%, p = 0.001). Median support duration was 24 days in all groups, and pre- and post-implant hemodynamic and laboratory improvements were comparable. Rates of transplantation (79% vs. 90%, p = 0.088) and LVAD implantation (2% vs. 6%, p = 0.159) did not differ significantly in the ≤58 mm cohort. Notably, within the ≤52 mm subgroup, 90-day survival remained high at 90.5% ( p = 0.336), with significant improvements in right atrial pressure (17 to 10 mmHg, p = 0.041), mean pulmonary artery pressure (36 to 26 mmHg, p = 0.008), and eGFR (45 to 57 mL/min/1.73m 2 , p = 0.003). Remarkably, native cardiac recovery was observed exclusively in the smaller LV cohorts, occurring in 11% of the ≤58 mm group ( p = 0.003 vs. 0%, p = 0.003) and reaching 19% in the ≤52 mm group (vs. 0% in larger cavities, p &lt; 0.001), while durable LVAD escalation was entirely avoided in the ≤52 mm cohort (0% vs. 6%). Ninety-day event-free survival was excellent across all cohorts 92% vs. 96% in the primary analysis, with no major device-related complications, suction events, clinically significant hemolysis, bleeding, stroke, or escalation to Bi-VAD support. These findings strongly support the safety and feasibility of Impella 5.5 in extremely constrained, small LV cavities.
Novel transplantable mouse cell line model recapitulates invasive lobular breast carcinoma (ILC) phenotype and immune microenvironment
Onkar, Sayali , Liu, Daisong, Seachrist, Darcie D. , Zou, Jian , Merkel, Christopher , Thale, Insa , Chang, Alexander Chih-Chieh , Klei, Linda R. , Chen, Jian, Weber-Bonk, Kristen L. , Rigatti, Laura, Workman, Creg J. , Oesterreich, Steffi , Seachrist, Darcie , Klei, Linda , Bonk, Kristen Weber , Ding, Kai , Savariau, Laura , Yates, Megan , Hooda, Jagmohan , Stabile, Laura , Lucas, Peter C , Ruth, Keri , Workman, Creg J , Lee, Adrian V , Vignali, Dario A A , Oesterreich, Steffi , Savariau, Laura , Lucas, Peter C. , Tseng, George , Lee, Adrian V.

Mayo Clinic

No container title available | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.30.741815 | PMID 42620030 Get It

Abstract Invasive lobular breast carcinoma (ILC) is the most common special histological subtype of breast cancer, which accounts for 10-15% of all cases. To study the phenotype characteristics, metastatic growth kinetic and immune microenvironment of ILC, we developed an orthotopically transplantable cell line model from the spontaneous mammary fat pad tumor of CDH1-PTEN dual knockout C57BL/6 mouse with Cre-loxP system, designated CPT6. CPT6 recapitulates single-file growth pattern of human ILC, with pleomorphic features and a high mitotic index. RNA sequencing together with whole exome sequencing reveals a luminal A subtype with targetable driver mutations such as Kras G12C. As a novel orthotopically transplantable ILC model in immune competent mice, CPT6 shows robust in vivo growth and metastatic rate, and has moderate immunogenicity which appears to be T-cell independent. We also profiled the immune microenvironment of CPT6, revealing a myeloid-rich environment with dominant M2-macrophage population, which is concordant with human ILC. In summary, this model recapitulates human ILC phenotype and represents a valuable preclinical platform for evaluating immunotherapy and other therapeutic strategies for invasive lobular breast carcinoma.
Breast cancer ovarian metastases show increased activity of GPCR pathways
Savariau, Laura , Qin, Ye, Shah, Osama Shiraz , Basudan, Ahmed , Merkel, Chris , Sisoudiya, Saumya D. , Sivakumar, Smruthy , Sokol, Ethan , McGinn, Olivia , Li, Zheqi , Liu, Tiantong , Tasdemir, Nilgun , Tallapaneni, Pooja , Oesterreich, Steffi , Shah, Osama , Basudan, Ahmed M , Coffman, Lan , Elishaev, Esther , Lucas, Peter C , Lee, Adrian V , Oesterreich, Steffi , Li, Zheqi , Savariau, Laura , Elishaev, Esther , Atkinson, Jennifer M. , Lucas, Peter C. , Lee, Adrian V.

Mayo Clinic

No container title available | August 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.30.741805 | PMID 42619866 Get It

Abstract Treatment resistance and metastases occur in 10–20% of patients with invasive lobular carcinoma (ILC), the most common special histological subtype of breast cancer. ILC metastasizes to the ovary more frequently than no special type (NST) tumors, also known as invasive ductal carcinoma (IDC). To characterize the genomic landscape of breast cancer ovarian metastases, we analyzed 15,613 local breast cancers, 22,010 non-ovarian metastases, and 246 ovarian metastases sequenced using FoundationOne®CDx or FoundationOne® assays. Ovarian metastases had enriched CDH1 , PIK3CA , and TBX3 mutations and depleted TP53 and MYC alterations relative to local breast cancers, with additional depletion of ESR1 mutations compared to non-ovarian metastases. CDH1 mutations were less frequent in ovarian metastases (47%) than local ILC (81.3%), with reduced 16q loss (64% vs 84%), indicating that ovarian metastases also arise from non-ILC tumors. We extended these findings to a UPMC cohort of 27 ovarian metastases (13 ILC, 8 IDC, 6 mixed ductal-lobular carcinoma) with patient-matched primary tumors in most cases. In both cohorts, patients with ovarian metastases were significantly younger than those with other metastatic sites. In the UPMC cohort, the most frequent mutations were in PIK3CA , CDH1 , KMT2C , FOXA1 , and RUNX1 . Transcriptomic analysis identified upregulated G protein-coupled receptor (GPCR) pathways, including metabotropic glutamate receptor signaling. Functional studies showed that calcium-sensing receptor (CaSR), a GPCR overexpressed in ovarian metastases, drives MEK/ERK-dependent migration and F-actin reorganization in ILC cell lines, enhanced by estrogen and blocked by calcilytic, MEK, or anti- estrogen treatment. Our findings inform future therapeutic targeting of ovarian metastasis.
Refining Shoulder Diagnostics: A Technical Note on Scapular Physical Examination
Selman, Farah , Perry, Nicholas P.J. , Restrepo, Diego J. , Coleman, David, Sánchez‐Sotelo, Joaquín , Perry, Nicholas Peter James , Restrepo, Diego J. , Sanchez-Sotelo, J.

Mayo Clinic

Arthroscopy Techniques | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/atn2.70203 | PMID 42541084 Get It

Abstract Normal scapulothoracic function relies on a delicate balance among several periscapular muscles and is essential for shoulder motion. Disturbance in this balance can lead to abnormal motion, which can impair shoulder function, leading to pain and discomfort. A thorough scapular examination requires an accurate physical assessment and the ability to identify pathologies, such as muscle paralysis (e.g., trapezius or serratus anterior) and hyperactivity (e.g., pectoralis minor). Overall, a comprehensive approach to the physical examination is critical in accurately diagnosing and effectively treating shoulder and scapular pathologies. The purpose of this technical note is to provide a concise, standardized methodology for performing a comprehensive scapular examination, focusing on key clinical tests, anatomical landmarks, and motion patterns.